nodes	percent_of_prediction	percent_of_DWPC	metapath
Pseudoephedrine—NFATC1—hair follicle—skin cancer	0.0379	0.114	CbGeAlD
Pseudoephedrine—IL2—blood vessel—skin cancer	0.0325	0.0975	CbGeAlD
Pseudoephedrine—IL2—neck—skin cancer	0.0233	0.0698	CbGeAlD
Pseudoephedrine—NFATC1—connective tissue—skin cancer	0.0182	0.0547	CbGeAlD
Pseudoephedrine—IL2—connective tissue—skin cancer	0.0167	0.05	CbGeAlD
Pseudoephedrine—IL2—epithelium—skin cancer	0.0158	0.0475	CbGeAlD
Pseudoephedrine—IL2—skin of body—skin cancer	0.015	0.0452	CbGeAlD
Pseudoephedrine—NFATC1—lymphoid tissue—skin cancer	0.0133	0.04	CbGeAlD
Pseudoephedrine—IL2—lymphoid tissue—skin cancer	0.0122	0.0366	CbGeAlD
Pseudoephedrine—IL2—female reproductive system—skin cancer	0.0118	0.0353	CbGeAlD
Pseudoephedrine—SLC6A3—nerve—skin cancer	0.0109	0.0328	CbGeAlD
Pseudoephedrine—NFATC1—head—skin cancer	0.0107	0.0322	CbGeAlD
Pseudoephedrine—IL2—head—skin cancer	0.00982	0.0295	CbGeAlD
Pseudoephedrine—SLC6A2—nerve—skin cancer	0.00882	0.0265	CbGeAlD
Pseudoephedrine—MAOA—nerve—skin cancer	0.00813	0.0244	CbGeAlD
Pseudoephedrine—NFATC1—lymph node—skin cancer	0.00752	0.0226	CbGeAlD
Pseudoephedrine—TNF—lymph node—skin cancer	0.00717	0.0215	CbGeAlD
Pseudoephedrine—IL2—lymph node—skin cancer	0.00688	0.0206	CbGeAlD
Pseudoephedrine—Cerebral haemorrhage—Temozolomide—skin cancer	0.00619	0.0313	CcSEcCtD
Pseudoephedrine—MAOA—nipple—skin cancer	0.00462	0.0138	CbGeAlD
Pseudoephedrine—MAOA—neck—skin cancer	0.00457	0.0137	CbGeAlD
Pseudoephedrine—Muscle spasms—Vismodegib—skin cancer	0.00456	0.0231	CcSEcCtD
Pseudoephedrine—ADRB1—connective tissue—skin cancer	0.00418	0.0125	CbGeAlD
Pseudoephedrine—Irritability—Imiquimod—skin cancer	0.00396	0.02	CcSEcCtD
Pseudoephedrine—Urinary retention—Imiquimod—skin cancer	0.00395	0.02	CcSEcCtD
Pseudoephedrine—ADRA2A—nipple—skin cancer	0.00354	0.0106	CbGeAlD
Pseudoephedrine—Dyspepsia—Vismodegib—skin cancer	0.00341	0.0172	CcSEcCtD
Pseudoephedrine—Decreased appetite—Vismodegib—skin cancer	0.00336	0.017	CcSEcCtD
Pseudoephedrine—Dysuria—Imiquimod—skin cancer	0.00335	0.017	CcSEcCtD
Pseudoephedrine—Pain—Vismodegib—skin cancer	0.00331	0.0168	CcSEcCtD
Pseudoephedrine—MAOA—connective tissue—skin cancer	0.00327	0.00982	CbGeAlD
Pseudoephedrine—ADRA1A—epithelium—skin cancer	0.00314	0.00941	CbGeAlD
Pseudoephedrine—ADRB1—female reproductive system—skin cancer	0.00295	0.00884	CbGeAlD
Pseudoephedrine—SLC6A4—female reproductive system—skin cancer	0.00285	0.00854	CbGeAlD
Pseudoephedrine—Asthenia—Vismodegib—skin cancer	0.00278	0.0141	CcSEcCtD
Pseudoephedrine—Euphoric mood—Fluorouracil—skin cancer	0.00271	0.0137	CcSEcCtD
Pseudoephedrine—MAOA—mammalian vulva—skin cancer	0.0027	0.00809	CbGeAlD
Pseudoephedrine—SLC6A3—head—skin cancer	0.00259	0.00778	CbGeAlD
Pseudoephedrine—Arrhythmia—Imiquimod—skin cancer	0.00256	0.013	CcSEcCtD
Pseudoephedrine—ADRA2A—connective tissue—skin cancer	0.00251	0.00753	CbGeAlD
Pseudoephedrine—SLC6A2—female reproductive system—skin cancer	0.00251	0.00752	CbGeAlD
Pseudoephedrine—ADRB1—head—skin cancer	0.00246	0.00738	CbGeAlD
Pseudoephedrine—Vomiting—Vismodegib—skin cancer	0.00246	0.0125	CcSEcCtD
Pseudoephedrine—Rash—Vismodegib—skin cancer	0.00244	0.0124	CcSEcCtD
Pseudoephedrine—Dermatitis—Vismodegib—skin cancer	0.00244	0.0123	CcSEcCtD
Pseudoephedrine—ADRA1A—lymphoid tissue—skin cancer	0.00242	0.00725	CbGeAlD
Pseudoephedrine—SLC6A4—head—skin cancer	0.00238	0.00713	CbGeAlD
Pseudoephedrine—MAOA—female reproductive system—skin cancer	0.00231	0.00693	CbGeAlD
Pseudoephedrine—Nausea—Vismodegib—skin cancer	0.0023	0.0116	CcSEcCtD
Pseudoephedrine—Agitation—Imiquimod—skin cancer	0.0023	0.0116	CcSEcCtD
Pseudoephedrine—Blood pressure increased—Docetaxel—skin cancer	0.00228	0.0115	CcSEcCtD
Pseudoephedrine—Palpitations—Imiquimod—skin cancer	0.00221	0.0112	CcSEcCtD
Pseudoephedrine—Irritability—Fluorouracil—skin cancer	0.00219	0.0111	CcSEcCtD
Pseudoephedrine—Hypertension—Imiquimod—skin cancer	0.00216	0.0109	CcSEcCtD
Pseudoephedrine—Chest pain—Imiquimod—skin cancer	0.00213	0.0108	CcSEcCtD
Pseudoephedrine—Anxiety—Imiquimod—skin cancer	0.00212	0.0107	CcSEcCtD
Pseudoephedrine—SLC6A2—head—skin cancer	0.00209	0.00628	CbGeAlD
Pseudoephedrine—Decreased appetite—Vemurafenib—skin cancer	0.00208	0.0105	CcSEcCtD
Pseudoephedrine—ADRA2A—mammalian vulva—skin cancer	0.00207	0.0062	CbGeAlD
Pseudoephedrine—Lightheadedness—Docetaxel—skin cancer	0.00204	0.0103	CcSEcCtD
Pseudoephedrine—Dysuria—Temozolomide—skin cancer	0.00201	0.0102	CcSEcCtD
Pseudoephedrine—Tachycardia—Imiquimod—skin cancer	0.00199	0.0101	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Imiquimod—skin cancer	0.00197	0.00998	CcSEcCtD
Pseudoephedrine—ADRA1A—head—skin cancer	0.00195	0.00584	CbGeAlD
Pseudoephedrine—Anorexia—Imiquimod—skin cancer	0.00194	0.00984	CcSEcCtD
Pseudoephedrine—Angina pectoris—Fluorouracil—skin cancer	0.00193	0.00976	CcSEcCtD
Pseudoephedrine—MAOA—head—skin cancer	0.00193	0.00579	CbGeAlD
Pseudoephedrine—Body temperature increased—Vemurafenib—skin cancer	0.00189	0.00957	CcSEcCtD
Pseudoephedrine—Insomnia—Imiquimod—skin cancer	0.00184	0.00934	CcSEcCtD
Pseudoephedrine—Dyspnoea—Imiquimod—skin cancer	0.00182	0.0092	CcSEcCtD
Pseudoephedrine—Dyspepsia—Imiquimod—skin cancer	0.0018	0.00909	CcSEcCtD
Pseudoephedrine—Decreased appetite—Imiquimod—skin cancer	0.00177	0.00897	CcSEcCtD
Pseudoephedrine—ADRA2A—female reproductive system—skin cancer	0.00177	0.00531	CbGeAlD
Pseudoephedrine—Pain—Imiquimod—skin cancer	0.00174	0.00883	CcSEcCtD
Pseudoephedrine—Asthenia—Vemurafenib—skin cancer	0.00172	0.00868	CcSEcCtD
Pseudoephedrine—Hallucination—Temozolomide—skin cancer	0.00171	0.00866	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Imiquimod—skin cancer	0.00168	0.00851	CcSEcCtD
Pseudoephedrine—Body temperature increased—Imiquimod—skin cancer	0.00161	0.00816	CcSEcCtD
Pseudoephedrine—Dizziness—Vemurafenib—skin cancer	0.00158	0.008	CcSEcCtD
Pseudoephedrine—Vomiting—Vemurafenib—skin cancer	0.00152	0.0077	CcSEcCtD
Pseudoephedrine—Chest pain—Bleomycin—skin cancer	0.00151	0.00765	CcSEcCtD
Pseudoephedrine—Rash—Vemurafenib—skin cancer	0.00151	0.00763	CcSEcCtD
Pseudoephedrine—Dermatitis—Vemurafenib—skin cancer	0.00151	0.00762	CcSEcCtD
Pseudoephedrine—Headache—Vemurafenib—skin cancer	0.0015	0.00758	CcSEcCtD
Pseudoephedrine—ADRA2A—head—skin cancer	0.00148	0.00444	CbGeAlD
Pseudoephedrine—SLC6A2—lymph node—skin cancer	0.00147	0.0044	CbGeAlD
Pseudoephedrine—Asthenia—Imiquimod—skin cancer	0.00146	0.00741	CcSEcCtD
Pseudoephedrine—Confusional state—Bleomycin—skin cancer	0.00146	0.00739	CcSEcCtD
Pseudoephedrine—Nausea—Vemurafenib—skin cancer	0.00142	0.00719	CcSEcCtD
Pseudoephedrine—Arrhythmia—Fluorouracil—skin cancer	0.00142	0.00717	CcSEcCtD
Pseudoephedrine—Tremor—Temozolomide—skin cancer	0.0014	0.0071	CcSEcCtD
Pseudoephedrine—Angina pectoris—Docetaxel—skin cancer	0.00139	0.00705	CcSEcCtD
Pseudoephedrine—Anorexia—Bleomycin—skin cancer	0.00138	0.00699	CcSEcCtD
Pseudoephedrine—Agitation—Temozolomide—skin cancer	0.00138	0.00697	CcSEcCtD
Pseudoephedrine—CYP2D6—female reproductive system—skin cancer	0.00137	0.00412	CbGeAlD
Pseudoephedrine—MAOA—lymph node—skin cancer	0.00135	0.00405	CbGeAlD
Pseudoephedrine—Dizziness—Imiquimod—skin cancer	0.00135	0.00683	CcSEcCtD
Pseudoephedrine—Vertigo—Temozolomide—skin cancer	0.00135	0.00681	CcSEcCtD
Pseudoephedrine—Palpitations—Temozolomide—skin cancer	0.00132	0.0067	CcSEcCtD
Pseudoephedrine—Vomiting—Imiquimod—skin cancer	0.0013	0.00656	CcSEcCtD
Pseudoephedrine—Hypertension—Temozolomide—skin cancer	0.00129	0.00654	CcSEcCtD
Pseudoephedrine—Dyspnoea—Bleomycin—skin cancer	0.00129	0.00654	CcSEcCtD
Pseudoephedrine—Anorexia—Dactinomycin—skin cancer	0.00129	0.00652	CcSEcCtD
Pseudoephedrine—Rash—Imiquimod—skin cancer	0.00129	0.00651	CcSEcCtD
Pseudoephedrine—Dermatitis—Imiquimod—skin cancer	0.00128	0.0065	CcSEcCtD
Pseudoephedrine—Headache—Imiquimod—skin cancer	0.00128	0.00647	CcSEcCtD
Pseudoephedrine—Anxiety—Temozolomide—skin cancer	0.00127	0.00643	CcSEcCtD
Pseudoephedrine—Decreased appetite—Bleomycin—skin cancer	0.00126	0.00637	CcSEcCtD
Pseudoephedrine—Pain—Bleomycin—skin cancer	0.00124	0.00627	CcSEcCtD
Pseudoephedrine—Confusional state—Temozolomide—skin cancer	0.00123	0.00624	CcSEcCtD
Pseudoephedrine—Nausea—Imiquimod—skin cancer	0.00121	0.00613	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Bleomycin—skin cancer	0.00119	0.00604	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Temozolomide—skin cancer	0.00118	0.00598	CcSEcCtD
Pseudoephedrine—Chest pain—Fluorouracil—skin cancer	0.00117	0.00595	CcSEcCtD
Pseudoephedrine—Decreased appetite—Dactinomycin—skin cancer	0.00117	0.00595	CcSEcCtD
Pseudoephedrine—Anorexia—Temozolomide—skin cancer	0.00116	0.0059	CcSEcCtD
Pseudoephedrine—Pain—Dactinomycin—skin cancer	0.00116	0.00585	CcSEcCtD
Pseudoephedrine—CYP2D6—head—skin cancer	0.00115	0.00344	CbGeAlD
Pseudoephedrine—Body temperature increased—Bleomycin—skin cancer	0.00115	0.0058	CcSEcCtD
Pseudoephedrine—Confusional state—Fluorouracil—skin cancer	0.00114	0.00575	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Dactinomycin—skin cancer	0.00111	0.00564	CcSEcCtD
Pseudoephedrine—Insomnia—Temozolomide—skin cancer	0.00111	0.00559	CcSEcCtD
Pseudoephedrine—Tachycardia—Fluorouracil—skin cancer	0.0011	0.00556	CcSEcCtD
Pseudoephedrine—Dyspnoea—Temozolomide—skin cancer	0.00109	0.00551	CcSEcCtD
Pseudoephedrine—Dyspepsia—Temozolomide—skin cancer	0.00108	0.00545	CcSEcCtD
Pseudoephedrine—Anorexia—Fluorouracil—skin cancer	0.00107	0.00543	CcSEcCtD
Pseudoephedrine—Body temperature increased—Dactinomycin—skin cancer	0.00107	0.00541	CcSEcCtD
Pseudoephedrine—Decreased appetite—Temozolomide—skin cancer	0.00106	0.00538	CcSEcCtD
Pseudoephedrine—Pain—Temozolomide—skin cancer	0.00105	0.00529	CcSEcCtD
Pseudoephedrine—Asthenia—Bleomycin—skin cancer	0.00104	0.00526	CcSEcCtD
Pseudoephedrine—ADRA2A—lymph node—skin cancer	0.00104	0.00311	CbGeAlD
Pseudoephedrine—Arrhythmia—Docetaxel—skin cancer	0.00102	0.00517	CcSEcCtD
Pseudoephedrine—Insomnia—Fluorouracil—skin cancer	0.00102	0.00515	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Temozolomide—skin cancer	0.00101	0.0051	CcSEcCtD
Pseudoephedrine—Dyspnoea—Fluorouracil—skin cancer	0.001	0.00508	CcSEcCtD
Pseudoephedrine—Dyspepsia—Fluorouracil—skin cancer	0.000991	0.00502	CcSEcCtD
Pseudoephedrine—Decreased appetite—Fluorouracil—skin cancer	0.000979	0.00495	CcSEcCtD
Pseudoephedrine—Asthenia—Dactinomycin—skin cancer	0.000969	0.00491	CcSEcCtD
Pseudoephedrine—Body temperature increased—Temozolomide—skin cancer	0.000966	0.00489	CcSEcCtD
Pseudoephedrine—Pain—Fluorouracil—skin cancer	0.000963	0.00487	CcSEcCtD
Pseudoephedrine—Muscle spasms—Docetaxel—skin cancer	0.000957	0.00485	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Fluorouracil—skin cancer	0.000928	0.0047	CcSEcCtD
Pseudoephedrine—Vomiting—Bleomycin—skin cancer	0.000921	0.00466	CcSEcCtD
Pseudoephedrine—Rash—Bleomycin—skin cancer	0.000913	0.00462	CcSEcCtD
Pseudoephedrine—Dermatitis—Bleomycin—skin cancer	0.000913	0.00462	CcSEcCtD
Pseudoephedrine—Body temperature increased—Fluorouracil—skin cancer	0.00089	0.00451	CcSEcCtD
Pseudoephedrine—Palpitations—Docetaxel—skin cancer	0.00088	0.00445	CcSEcCtD
Pseudoephedrine—Asthenia—Temozolomide—skin cancer	0.000877	0.00444	CcSEcCtD
Pseudoephedrine—Nausea—Bleomycin—skin cancer	0.000861	0.00436	CcSEcCtD
Pseudoephedrine—Hypertension—Docetaxel—skin cancer	0.00086	0.00435	CcSEcCtD
Pseudoephedrine—Vomiting—Dactinomycin—skin cancer	0.000859	0.00435	CcSEcCtD
Pseudoephedrine—Rash—Dactinomycin—skin cancer	0.000852	0.00431	CcSEcCtD
Pseudoephedrine—Chest pain—Docetaxel—skin cancer	0.000848	0.00429	CcSEcCtD
Pseudoephedrine—Confusional state—Docetaxel—skin cancer	0.000819	0.00415	CcSEcCtD
Pseudoephedrine—Dizziness—Temozolomide—skin cancer	0.000808	0.00409	CcSEcCtD
Pseudoephedrine—Nausea—Dactinomycin—skin cancer	0.000803	0.00406	CcSEcCtD
Pseudoephedrine—Tachycardia—Docetaxel—skin cancer	0.000793	0.00401	CcSEcCtD
Pseudoephedrine—Vomiting—Temozolomide—skin cancer	0.000777	0.00393	CcSEcCtD
Pseudoephedrine—Anorexia—Docetaxel—skin cancer	0.000775	0.00392	CcSEcCtD
Pseudoephedrine—Rash—Temozolomide—skin cancer	0.000771	0.0039	CcSEcCtD
Pseudoephedrine—Dermatitis—Temozolomide—skin cancer	0.00077	0.0039	CcSEcCtD
Pseudoephedrine—Headache—Temozolomide—skin cancer	0.000766	0.00388	CcSEcCtD
Pseudoephedrine—Dizziness—Fluorouracil—skin cancer	0.000745	0.00377	CcSEcCtD
Pseudoephedrine—Insomnia—Docetaxel—skin cancer	0.000735	0.00372	CcSEcCtD
Pseudoephedrine—Nausea—Temozolomide—skin cancer	0.000726	0.00367	CcSEcCtD
Pseudoephedrine—Dyspnoea—Docetaxel—skin cancer	0.000725	0.00367	CcSEcCtD
Pseudoephedrine—Vomiting—Fluorouracil—skin cancer	0.000716	0.00362	CcSEcCtD
Pseudoephedrine—Dyspepsia—Docetaxel—skin cancer	0.000715	0.00362	CcSEcCtD
Pseudoephedrine—Rash—Fluorouracil—skin cancer	0.00071	0.00359	CcSEcCtD
Pseudoephedrine—Dermatitis—Fluorouracil—skin cancer	0.000709	0.00359	CcSEcCtD
Pseudoephedrine—Decreased appetite—Docetaxel—skin cancer	0.000707	0.00358	CcSEcCtD
Pseudoephedrine—Headache—Fluorouracil—skin cancer	0.000705	0.00357	CcSEcCtD
Pseudoephedrine—Pain—Docetaxel—skin cancer	0.000695	0.00352	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Docetaxel—skin cancer	0.00067	0.00339	CcSEcCtD
Pseudoephedrine—Nausea—Fluorouracil—skin cancer	0.000669	0.00339	CcSEcCtD
Pseudoephedrine—Body temperature increased—Docetaxel—skin cancer	0.000642	0.00325	CcSEcCtD
Pseudoephedrine—Asthenia—Docetaxel—skin cancer	0.000583	0.00295	CcSEcCtD
Pseudoephedrine—Dizziness—Docetaxel—skin cancer	0.000537	0.00272	CcSEcCtD
Pseudoephedrine—Vomiting—Docetaxel—skin cancer	0.000517	0.00262	CcSEcCtD
Pseudoephedrine—Rash—Docetaxel—skin cancer	0.000512	0.00259	CcSEcCtD
Pseudoephedrine—Dermatitis—Docetaxel—skin cancer	0.000512	0.00259	CcSEcCtD
Pseudoephedrine—Headache—Docetaxel—skin cancer	0.000509	0.00258	CcSEcCtD
Pseudoephedrine—Nausea—Docetaxel—skin cancer	0.000483	0.00244	CcSEcCtD
Pseudoephedrine—ADRB1—Signaling by GPCR—PTCH2—skin cancer	0.000402	0.000856	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000395	0.000843	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR ligand binding—SHH—skin cancer	0.000394	0.000841	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—RHOU—skin cancer	0.000393	0.000838	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—PTCH2—skin cancer	0.000393	0.000838	CbGpPWpGaD
Pseudoephedrine—TNF—Alzheimers Disease—TP53—skin cancer	0.000392	0.000835	CbGpPWpGaD
Pseudoephedrine—TNF—TNF alpha Signaling Pathway—KRAS—skin cancer	0.00039	0.000831	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—SHH—skin cancer	0.00039	0.00083	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—RASA1—skin cancer	0.000387	0.000825	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR ligand binding—PTCH1—skin cancer	0.000382	0.000815	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR ligand binding—SMO—skin cancer	0.000382	0.000815	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—ERCC2—skin cancer	0.000382	0.000814	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—FOXO4—skin cancer	0.000375	0.0008	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR ligand binding—PTCH1—skin cancer	0.000374	0.000797	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR ligand binding—SMO—skin cancer	0.000374	0.000797	CbGpPWpGaD
Pseudoephedrine—TNF—Apoptosis—TP53—skin cancer	0.000373	0.000795	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR ligand binding—PTGER4—skin cancer	0.000372	0.000793	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—SMO—skin cancer	0.000369	0.000787	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—PTCH1—skin cancer	0.000369	0.000787	CbGpPWpGaD
Pseudoephedrine—MAOA—Transmission across Chemical Synapses—BRAF—skin cancer	0.000368	0.000784	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000367	0.000783	CbGpPWpGaD
Pseudoephedrine—IL2—Cytokine Signaling in Immune system—HRAS—skin cancer	0.000366	0.00078	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—RHOU—skin cancer	0.000365	0.000779	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR ligand binding—PTGER4—skin cancer	0.000364	0.000776	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—PTGER4—skin cancer	0.00036	0.000766	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—TERT—skin cancer	0.000358	0.000763	CbGpPWpGaD
Pseudoephedrine—IL2—Cytokine Signaling in Immune system—IL6—skin cancer	0.00035	0.000746	CbGpPWpGaD
Pseudoephedrine—SLC6A3—Transmission across Chemical Synapses—BRAF—skin cancer	0.000342	0.000728	CbGpPWpGaD
Pseudoephedrine—TNF—TNF alpha Signaling Pathway—HRAS—skin cancer	0.000332	0.000707	CbGpPWpGaD
Pseudoephedrine—NFATC1—Innate Immune System—NRAS—skin cancer	0.000331	0.000707	CbGpPWpGaD
Pseudoephedrine—TNF—Selenium Micronutrient Network—IL6—skin cancer	0.000329	0.000701	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR ligand binding—SHH—skin cancer	0.000326	0.000695	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—PTCH2—skin cancer	0.000325	0.000693	CbGpPWpGaD
Pseudoephedrine—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.000325	0.000692	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—MC1R—skin cancer	0.00032	0.000682	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—FOXO4—skin cancer	0.000318	0.000677	CbGpPWpGaD
Pseudoephedrine—TNF—TNF alpha Signaling Pathway—IL6—skin cancer	0.000317	0.000676	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—MC1R—skin cancer	0.000313	0.000667	CbGpPWpGaD
Pseudoephedrine—IL2—Hemostasis—NRAS—skin cancer	0.000311	0.000664	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR ligand binding—SMO—skin cancer	0.000309	0.000659	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR ligand binding—PTCH1—skin cancer	0.000309	0.000659	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR ligand binding—SHH—skin cancer	0.000303	0.000646	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—PTCH2—skin cancer	0.000302	0.000644	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR ligand binding—PTGER4—skin cancer	0.000301	0.000642	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PLIN2—skin cancer	0.0003	0.00064	CbGpPWpGaD
Pseudoephedrine—ADRA1A—AMPK Signaling—TP53—skin cancer	0.000298	0.000635	CbGpPWpGaD
Pseudoephedrine—TNF—Toll-like Receptor Signaling Pathway—IL6—skin cancer	0.000292	0.000623	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—MC1R—skin cancer	0.00029	0.000619	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR ligand binding—PTCH1—skin cancer	0.000287	0.000613	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR ligand binding—SMO—skin cancer	0.000287	0.000613	CbGpPWpGaD
Pseudoephedrine—NFATC1—Innate Immune System—KRAS—skin cancer	0.000285	0.000608	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—MC1R—skin cancer	0.000284	0.000606	CbGpPWpGaD
Pseudoephedrine—TNF—Spinal Cord Injury—TP53—skin cancer	0.000284	0.000605	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—BRAF—skin cancer	0.000284	0.000605	CbGpPWpGaD
Pseudoephedrine—MAOA—Neuronal System—BRAF—skin cancer	0.000282	0.0006	CbGpPWpGaD
Pseudoephedrine—TNF—MAPK Signaling Pathway—NRAS—skin cancer	0.00028	0.000597	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR ligand binding—PTGER4—skin cancer	0.00028	0.000596	CbGpPWpGaD
Pseudoephedrine—IL2—Hemostasis—KRAS—skin cancer	0.000268	0.000571	CbGpPWpGaD
Pseudoephedrine—SLC6A3—Neuronal System—BRAF—skin cancer	0.000262	0.000558	CbGpPWpGaD
Pseudoephedrine—TNF—Spinal Cord Injury—IL6—skin cancer	0.00026	0.000554	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—MC1R—skin cancer	0.000259	0.000552	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—TERT—skin cancer	0.000251	0.000535	CbGpPWpGaD
Pseudoephedrine—NFATC1—Innate Immune System—HRAS—skin cancer	0.000242	0.000517	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—CSPG4—skin cancer	0.000242	0.000516	CbGpPWpGaD
Pseudoephedrine—TNF—MAPK Signaling Pathway—KRAS—skin cancer	0.000241	0.000514	CbGpPWpGaD
Pseudoephedrine—SLC6A4—SIDS Susceptibility Pathways—IL6—skin cancer	0.000241	0.000513	CbGpPWpGaD
Pseudoephedrine—TNF—Adipogenesis—IL6—skin cancer	0.000241	0.000513	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—MC1R—skin cancer	0.00024	0.000512	CbGpPWpGaD
Pseudoephedrine—IL2—Hemostasis—TP53—skin cancer	0.000238	0.000508	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PTCH2—skin cancer	0.000237	0.000506	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—MC1R—skin cancer	0.000235	0.000501	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PTCH2—skin cancer	0.000232	0.000495	CbGpPWpGaD
Pseudoephedrine—NFATC1—Innate Immune System—IL6—skin cancer	0.000232	0.000495	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—PTGS2—skin cancer	0.000229	0.000488	CbGpPWpGaD
Pseudoephedrine—TNF—Apoptosis—TP53—skin cancer	0.000228	0.000487	CbGpPWpGaD
Pseudoephedrine—TNF—Regulation of toll-like receptor signaling pathway—IL6—skin cancer	0.000228	0.000486	CbGpPWpGaD
Pseudoephedrine—IL2—Hemostasis—HRAS—skin cancer	0.000228	0.000486	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—MC1R—skin cancer	0.000218	0.000465	CbGpPWpGaD
Pseudoephedrine—TNF—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	0.000217	0.000463	CbGpPWpGaD
Pseudoephedrine—SLC6A4—Circadian rythm related genes—TP53—skin cancer	0.000215	0.000458	CbGpPWpGaD
Pseudoephedrine—TNF—MAPK Signaling Pathway—TP53—skin cancer	0.000214	0.000456	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—CDK4—skin cancer	0.000212	0.000453	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—TERT—skin cancer	0.000212	0.000452	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—PTGER4—skin cancer	0.00021	0.000448	CbGpPWpGaD
Pseudoephedrine—TNF—SIDS Susceptibility Pathways—IL6—skin cancer	0.000208	0.000443	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—SHH—skin cancer	0.000207	0.000441	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—PTGER4—skin cancer	0.000206	0.000438	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—SHH—skin cancer	0.000202	0.000431	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PLIN2—skin cancer	0.000201	0.000428	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—BRAF—skin cancer	0.000199	0.000423	CbGpPWpGaD
Pseudoephedrine—MAOA—SIDS Susceptibility Pathways—IL6—skin cancer	0.000197	0.000421	CbGpPWpGaD
Pseudoephedrine—SLC6A4—Circadian rythm related genes—IL6—skin cancer	0.000197	0.000419	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—PTCH1—skin cancer	0.000196	0.000418	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—SMO—skin cancer	0.000196	0.000418	CbGpPWpGaD
Pseudoephedrine—TNF—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	0.000193	0.000412	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—NRAS—skin cancer	0.000193	0.000412	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PTCH2—skin cancer	0.000192	0.000409	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—SMO—skin cancer	0.000192	0.000409	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—PTCH1—skin cancer	0.000192	0.000409	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—PTGER4—skin cancer	0.000191	0.000407	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—PTGER4—skin cancer	0.000187	0.000398	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—GLI2—skin cancer	0.00018	0.000383	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by GPCR—NRAS—skin cancer	0.000179	0.000381	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PTCH2—skin cancer	0.000178	0.00038	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—NRAS—skin cancer	0.000178	0.00038	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—GLI2—skin cancer	0.000176	0.000375	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MC1R—skin cancer	0.000172	0.000366	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—PTGER4—skin cancer	0.00017	0.000363	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—GLI1—skin cancer	0.000169	0.00036	CbGpPWpGaD
Pseudoephedrine—MAOA—Transmission across Chemical Synapses—HRAS—skin cancer	0.000169	0.00036	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—BRAF—skin cancer	0.000168	0.000358	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MC1R—skin cancer	0.000168	0.000358	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—SHH—skin cancer	0.000167	0.000357	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—KRAS—skin cancer	0.000166	0.000354	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—GLI1—skin cancer	0.000165	0.000353	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—ENO2—skin cancer	0.000164	0.000351	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—NRAS—skin cancer	0.000163	0.000348	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—CSPG4—skin cancer	0.000162	0.000345	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—SUFU—skin cancer	0.00016	0.000342	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—SMO—skin cancer	0.000159	0.000338	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—PTCH1—skin cancer	0.000159	0.000338	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—PTGER4—skin cancer	0.000158	0.000337	CbGpPWpGaD
Pseudoephedrine—SLC6A3—Transmission across Chemical Synapses—HRAS—skin cancer	0.000157	0.000335	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—SUFU—skin cancer	0.000157	0.000334	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000157	0.000334	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—SHH—skin cancer	0.000156	0.000332	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—PTGER4—skin cancer	0.000155	0.000329	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by GPCR—KRAS—skin cancer	0.000154	0.000328	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—KRAS—skin cancer	0.000153	0.000327	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—SMO—skin cancer	0.000147	0.000314	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—PTCH1—skin cancer	0.000147	0.000314	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—GLI2—skin cancer	0.000146	0.00031	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—PTGER4—skin cancer	0.000144	0.000306	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—HRAS—skin cancer	0.000141	0.000301	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—KRAS—skin cancer	0.000141	0.0003	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MC1R—skin cancer	0.000139	0.000296	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—GLI1—skin cancer	0.000137	0.000292	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—GLI2—skin cancer	0.000135	0.000288	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—IL6—skin cancer	0.000135	0.000288	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000135	0.000288	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by GPCR—HRAS—skin cancer	0.000131	0.000279	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PLIN2—skin cancer	0.000131	0.000279	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—HRAS—skin cancer	0.00013	0.000278	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—SUFU—skin cancer	0.00013	0.000276	CbGpPWpGaD
Pseudoephedrine—MAOA—Neuronal System—HRAS—skin cancer	0.00013	0.000276	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MC1R—skin cancer	0.000129	0.000275	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—GLI1—skin cancer	0.000127	0.000271	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by GPCR—IL6—skin cancer	0.000125	0.000267	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—NRAS—skin cancer	0.000125	0.000266	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—IL6—skin cancer	0.000125	0.000266	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—SHH—skin cancer	0.000122	0.000261	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—RASA1—skin cancer	0.000121	0.000259	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—SUFU—skin cancer	0.00012	0.000257	CbGpPWpGaD
Pseudoephedrine—SLC6A3—Neuronal System—HRAS—skin cancer	0.00012	0.000257	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—SHH—skin cancer	0.00012	0.000255	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—HRAS—skin cancer	0.000119	0.000255	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—RASA1—skin cancer	0.000119	0.000253	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—NRAS—skin cancer	0.000118	0.000252	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PTCH1—skin cancer	0.000116	0.000247	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—SMO—skin cancer	0.000116	0.000247	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000115	0.000245	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—IL6—skin cancer	0.000114	0.000244	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—SMO—skin cancer	0.000113	0.000242	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PTCH1—skin cancer	0.000113	0.000242	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PTGER4—skin cancer	0.000113	0.00024	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PTGER4—skin cancer	0.00011	0.000235	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—ENO2—skin cancer	0.00011	0.000234	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.00011	0.000234	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—KRAS—skin cancer	0.000107	0.000229	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—NRAS—skin cancer	0.000106	0.000225	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CSPG4—skin cancer	0.000105	0.000225	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—KRAS—skin cancer	0.000102	0.000217	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—FOXO4—skin cancer	9.96e-05	0.000212	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—SHH—skin cancer	9.89e-05	0.000211	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—RASA1—skin cancer	9.83e-05	0.00021	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—FOXO4—skin cancer	9.75e-05	0.000208	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—ERCC2—skin cancer	9.55e-05	0.000204	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—TP53—skin cancer	9.55e-05	0.000204	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—SMO—skin cancer	9.38e-05	0.0002	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PTCH1—skin cancer	9.38e-05	0.0002	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—SHH—skin cancer	9.19e-05	0.000196	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—RASA1—skin cancer	9.13e-05	0.000195	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—HRAS—skin cancer	9.13e-05	0.000195	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PTGER4—skin cancer	9.13e-05	0.000195	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—KRAS—skin cancer	9.09e-05	0.000194	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—IL6—skin cancer	8.74e-05	0.000186	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PTCH1—skin cancer	8.71e-05	0.000186	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—SMO—skin cancer	8.71e-05	0.000186	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—HRAS—skin cancer	8.64e-05	0.000184	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PTGER4—skin cancer	8.48e-05	0.000181	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—IL6—skin cancer	8.27e-05	0.000176	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—TP53—skin cancer	8.08e-05	0.000172	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—FOXO4—skin cancer	8.06e-05	0.000172	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—HRAS—skin cancer	7.72e-05	0.000165	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—FOXO4—skin cancer	7.49e-05	0.00016	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—IL6—skin cancer	7.39e-05	0.000158	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—NRAS—skin cancer	7.35e-05	0.000157	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ENO2—skin cancer	7.16e-05	0.000153	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—TERT—skin cancer	6.66e-05	0.000142	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—TERT—skin cancer	6.51e-05	0.000139	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—ERCC2—skin cancer	6.38e-05	0.000136	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—KRAS—skin cancer	6.32e-05	0.000135	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PTGS2—skin cancer	5.73e-05	0.000122	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—TP53—skin cancer	5.62e-05	0.00012	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—NRAS—skin cancer	5.61e-05	0.00012	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—NRAS—skin cancer	5.49e-05	0.000117	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TERT—skin cancer	5.39e-05	0.000115	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—HRAS—skin cancer	5.37e-05	0.000115	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—BRAF—skin cancer	5.27e-05	0.000112	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—BRAF—skin cancer	5.16e-05	0.00011	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TERT—skin cancer	5e-05	0.000107	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—KRAS—skin cancer	4.83e-05	0.000103	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—KRAS—skin cancer	4.72e-05	0.000101	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—NRAS—skin cancer	4.54e-05	9.67e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—BRAF—skin cancer	4.26e-05	9.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—NRAS—skin cancer	4.22e-05	8.99e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ERCC2—skin cancer	4.16e-05	8.87e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—HRAS—skin cancer	4.1e-05	8.74e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—HRAS—skin cancer	4.01e-05	8.55e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—BRAF—skin cancer	3.96e-05	8.45e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—IL6—skin cancer	3.93e-05	8.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—KRAS—skin cancer	3.91e-05	8.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—IL6—skin cancer	3.84e-05	8.19e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PTGS2—skin cancer	3.83e-05	8.16e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—KRAS—skin cancer	3.63e-05	7.73e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—HRAS—skin cancer	3.32e-05	7.08e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—NRAS—skin cancer	3.31e-05	7.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—NRAS—skin cancer	3.24e-05	6.91e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—IL6—skin cancer	3.18e-05	6.77e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—HRAS—skin cancer	3.08e-05	6.57e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—IL6—skin cancer	2.95e-05	6.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—KRAS—skin cancer	2.85e-05	6.08e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—KRAS—skin cancer	2.79e-05	5.94e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—NRAS—skin cancer	2.68e-05	5.71e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—TP53—skin cancer	2.53e-05	5.4e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PTGS2—skin cancer	2.49e-05	5.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—NRAS—skin cancer	2.49e-05	5.31e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—TP53—skin cancer	2.48e-05	5.28e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—HRAS—skin cancer	2.42e-05	5.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—HRAS—skin cancer	2.37e-05	5.05e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IL6—skin cancer	2.32e-05	4.94e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KRAS—skin cancer	2.31e-05	4.92e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IL6—skin cancer	2.27e-05	4.84e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KRAS—skin cancer	2.14e-05	4.57e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TP53—skin cancer	2.05e-05	4.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—HRAS—skin cancer	1.96e-05	4.18e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TP53—skin cancer	1.91e-05	4.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IL6—skin cancer	1.88e-05	4e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—HRAS—skin cancer	1.82e-05	3.88e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IL6—skin cancer	1.74e-05	3.72e-05	CbGpPWpGaD
